2 Drug Development for Prostate Cancer Patients

Advancements in medicine and technology are changing the way healthcare providers approach patient diagnosis and treatment. For patients, there are now more options for addressing health concerns that can minimize invasive techniques. When it comes to dealing with prostate cancer, many men remain uninformed about the possibilities that exist. Treatment options have moved beyond a dependence on urology lasers. Although effective, there are always concerns with potential side effects of impotence or incontinence when treating prostate cancer when surgery is a treatment option. However, men around the world should be encouraged by two new developments in prostate cancer treatment that have been introduced to the medical field.

1. Darolutamide

As a second-generation androgen receptor, patients who have been diagnosed with a non-metastatic and castration-resistance prostate concerns may be helped by the new drug darolutamide. In the studies conducted, when this medication was added to an androgen depletion therapy (ADT), metastasis or death was delayed by an average of 22 months. The reduced the risk for death or metastasis by almost 59%. The early stages and uses of this drug have not been able to reveal the impact on overall survival, but with the projected results, this will achieve about a 30% reduction in the risk of death.

2. Enzalutamide

If a male suffers from metastatic hormone-sensitive prostate cancer (mHSPC), the inclusion of enzalutamide with ADT can help slow the growth of cancer. In the results of the study with this inclusion, the chances of tumor growth on scans or cases of patient death were reduced by 61%. The treatment was seen effective with all types of mHSPC patients, where there were high or low levels of metastases or if they had been treated with docetaxel. The long-term survival rates are looking promising.

For men suffering from prostate cancer, these drugs provide new opportunities for increased life-span and reduced metastasis risk. Even still, being proactive in early cancer screenings is the best way to improve the chances of treatment success.